Sanath K Meegalla

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi Synthesis and insecticidal activity of fluorinated 2-(2,6-dichloro-4-trifluoromethylphenyl)-2,4,5,6-tetrahydrocyclopentapyrazoles
    Sanath K Meegalla
    Johnson and Johnson Pharmaceutical Research and Development, 665 Stockton Drive, Suite 104, Exton, PA 19341, USA
    Bioorg Med Chem Lett 16:1702-6. 2006
  2. ncbi Structure-based optimization of a potent class of arylamide FMS inhibitors
    Sanath K Meegalla
    Johnson and Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, PA 19477, USA
    Bioorg Med Chem Lett 18:3632-7. 2008
  3. ncbi Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors
    Kenneth J Wilson
    Johnson and Johnson Pharmaceutical Research and Development, Spring House, PA 19477, USA
    Bioorg Med Chem Lett 20:3925-9. 2010
  4. ncbi 5-amino-1-(2,6-dichloro-4-trifluoromethyl-phenyl)-3-[3H3]-methylsulfanyl-1H-pyrazole-4-carbonitrile (CTOM): synthesis and characterization of a novel and selective insect GABA receptor radioligand
    Sanath K Meegalla
    3 Dimensional Pharmaceuticals, Inc, 665 Stockton Drive, Suite 104, Exton, PA 19341, USA
    Bioorg Med Chem Lett 13:4035-7. 2003
  5. ncbi Synthesis and GABA receptor potency of 3-thiomethyl-4-(hetero)aryl-5-amino-1-phenylpyrazoles
    Sanath K Meegalla
    3 Dimensional Pharmaceuticals, Inc, A wholly owned Johnson and Johnson company, 665 Stockton Drive, Exton, PA 1934, USA
    Bioorg Med Chem Lett 14:4949-53. 2004
  6. ncbi Discovery of novel FMS kinase inhibitors as anti-inflammatory agents
    Carl R Illig
    Johnson and Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, PA 19477, USA
    Bioorg Med Chem Lett 18:1642-8. 2008
  7. ncbi JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia
    Carl L Manthey
    Johnson and Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, PA 19477, USA
    Mol Cancer Ther 8:3151-61. 2009

Collaborators

Detail Information

Publications7

  1. ncbi Synthesis and insecticidal activity of fluorinated 2-(2,6-dichloro-4-trifluoromethylphenyl)-2,4,5,6-tetrahydrocyclopentapyrazoles
    Sanath K Meegalla
    Johnson and Johnson Pharmaceutical Research and Development, 665 Stockton Drive, Suite 104, Exton, PA 19341, USA
    Bioorg Med Chem Lett 16:1702-6. 2006
    ..A number of fluorinated 1-aryl-tetrahydrocyclopentapyrazoles were synthesized and their insecticidal activity was evaluated. Some of the fluorinated compounds had significant insecticidal properties...
  2. ncbi Structure-based optimization of a potent class of arylamide FMS inhibitors
    Sanath K Meegalla
    Johnson and Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, PA 19477, USA
    Bioorg Med Chem Lett 18:3632-7. 2008
    ..Structure-based modeling provided the framework to efficiently effect this transformation and restore potencies to previous levels. This optimization removed a risk factor for potential idiosyncratic drug reactions...
  3. ncbi Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors
    Kenneth J Wilson
    Johnson and Johnson Pharmaceutical Research and Development, Spring House, PA 19477, USA
    Bioorg Med Chem Lett 20:3925-9. 2010
    ..The resultant compounds retained excellent potency and exhibited diminished ion channel activity...
  4. ncbi 5-amino-1-(2,6-dichloro-4-trifluoromethyl-phenyl)-3-[3H3]-methylsulfanyl-1H-pyrazole-4-carbonitrile (CTOM): synthesis and characterization of a novel and selective insect GABA receptor radioligand
    Sanath K Meegalla
    3 Dimensional Pharmaceuticals, Inc, 665 Stockton Drive, Suite 104, Exton, PA 19341, USA
    Bioorg Med Chem Lett 13:4035-7. 2003
    ..It is 500-fold selective against the mammalian receptor (mouse brain preparations). Its specifically tritiated version (2b) was synthesized by reduction of disulfide 10 with NaBH(4) followed by alkylation with [3H(3)]-CH(3)I...
  5. ncbi Synthesis and GABA receptor potency of 3-thiomethyl-4-(hetero)aryl-5-amino-1-phenylpyrazoles
    Sanath K Meegalla
    3 Dimensional Pharmaceuticals, Inc, A wholly owned Johnson and Johnson company, 665 Stockton Drive, Exton, PA 1934, USA
    Bioorg Med Chem Lett 14:4949-53. 2004
    ..The potential for insecticidal activity through GABA channel blockage by this series of compounds, as well as their selectivity for insect versus mammalian receptors, are explored through in vitro and in vivo assays...
  6. ncbi Discovery of novel FMS kinase inhibitors as anti-inflammatory agents
    Carl R Illig
    Johnson and Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, PA 19477, USA
    Bioorg Med Chem Lett 18:1642-8. 2008
    ..Compound 8 (FMS kinase IC(50)=0.0008 microM) served as a proof-of-concept candidate in a collagen-induced model of arthritis in mice...
  7. ncbi JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia
    Carl L Manthey
    Johnson and Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, PA 19477, USA
    Mol Cancer Ther 8:3151-61. 2009
    ....